Keros Therapeutics vs Prothena Corp Public
KROS and PRTA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KROS and PRTA compare
Prothena Corp Public is the larger company, worth 2.1 times as much as Keros Therapeutics ($419M against $204M).
Prothena Corp Public grew revenue faster over the last twelve months (347% versus −83.4% for Keros Therapeutics).
Prothena Corp Public keeps more of each dollar of sales as profit, with a net margin of −45.4% compared with −153% at Keros Therapeutics.
Prothena Corp Public scores higher on the StockData Score (12 against 9 for Keros Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KROS | PRTA |
|---|---|---|
| Size and price | ||
| Market cap | $204M | $419M |
| Share price | $10.30 | $8.16 |
| Change, 1 year | −41.0% | −24.8% |
| Change, 5 years | −82.8% | −86.1% |
| Beta (5Y) | 1.11 | 0.86 |
| Employees | 78 | 67 |
| StockData Score | ||
| Total score | 9 | 12 (better) |
| Valuation score | 3 (better) | 2 |
| Growth score | 0 | 1 (better) |
| Performance score | 1 | 3 (better) |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 5.1× (better) | 7.9× |
| P/B | 0.7× (better) | 1.6× |
| FCF yield | −23.6% | – |
| Fair value | $24.09 | $9.83 |
| Margin of safety | 57.3% (better) | 17.0% |
| Growth | ||
| Revenue growth (TTM) | −83.4% | 347% (better) |
| Revenue growth, 5Y average | – | 62.6% |
| Net income growth (TTM) | −196% | – |
| EPS growth (TTM) | −282% | – |
| Profitability | ||
| Operating margin | −181% | −64.6% (better) |
| Net margin | −153% | −45.4% (better) |
| FCF margin | −119% | – |
| Return on equity | −12.6% | −8.5% (better) |
| Return on invested capital | −389% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 18.14 | 23.95 (better) |
| Altman Z-score | 2.37 | 11.36 (better) |
| Piotroski F-score | 6 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 101% | 92.2% |
| Held by insiders | 53.3% | 32.0% |
| Insider net buying, 12 months | −$447K | $13.1M (better) |
| Short interest, % of float | 11.7% | 22.7% |
Go deeper
- KROS stock overview
- KROS income statement
- KROS valuation and score
- PRTA stock overview
- PRTA income statement
- PRTA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.